Belite Bio Inc ADR (BLTE) Stock Forecast & Price Target
Belite Bio Inc ADR · NASDAQ
$158.60+5.24 (+3.42%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Belite Bio Inc ADR, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $132.00 to $266.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $201.50 sits 27% above the current $158.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.82 next quarter toward $0.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Belite Bio Inc ADR.
As of Jul, 6 of 6 firms rate BLTE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BLTE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.82
Range $-1.17 – $-0.53 · 7 analysts · +26% YoY
Next period, 7 analysts expect Belite Bio Inc ADR to earn $-0.82 a share (range $-1.17 – $-0.53), versus $-0.65 a year earlier. Full-year consensus is $-3.30, growing to $0.95 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $242.8M next year.
Top analysts covering Belite Bio Inc ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BLTE.
#1
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$200.00+26.1% to target
Overall win rate
34%
+ Follow
#2
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$195.00+23.0% to target
Overall win rate
41%
+ Follow
#3
Bruce Jackson
Benchmark · Rank #317
Buy
$217.00+36.8% to target
Overall win rate
35%
+ Follow
#4
Jason McCarthy
Maxim Group · Rank #360
Buy
$110.00-30.6% to target
Overall win rate
30%
+ Follow
#5
Graig Suvannavejh
Mizuho
Buy
$215.00+35.6% to target
Coverage
—
+ Follow
BLTE stock forecast FAQ
What is BLTE's average 12-month price target?+
The 6 analysts with a live target average $201.50 for Belite Bio Inc ADR over the next 12 months, ranging from a $266.00 high to a $132.00 low.
Is BLTE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BLTE?+
The Street-high target is $266.00 (Cantor Fitzgerald), and the Street-low is $132.00 (Benchmark). The average of all 6 active targets is $201.50.
How many Wall Street analysts cover BLTE?+
6 analysts have an active rating on Belite Bio Inc ADR, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering BLTE?+
Among analysts who currently cover BLTE, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #238). Their current call is Buy with a $200.00 target.
What is Belite Bio Inc ADR's projected EPS for next quarter?+
The consensus estimate is $-0.82 per share (range $-1.17 – $-0.53) across 7 analysts. Full-year EPS is projected at $-3.30, rising to $0.95 the following year.
How much revenue is Belite Bio Inc ADR expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $242.8M next year.
Have analysts been upgrading or downgrading BLTE lately?+
As of Jul, 6 of 6 firms rate BLTE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BLTE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
